The PRESBYLENS™ Corneal Inlay (CI), developed by ReVision Optics, is a corneal inlay designed to correct presbyopia by changing the shape of the eye’s corneal surface. Several years ago, the Presbylens raised hopes of a reversible treatment for presbyopia for at least some patients.

However, according to a recent article in The Review of Ophthalmology, various issues arose that ReVision had to address. For example, the Presbylens was originally 1.5 mm in diameter, but this caused issues with the size of the area that patients could view accurately; a new version is now 2 mm in diameter and patient complaints have stopped. There were also some initial issues with haze postop.

The same article reports that a redesigned Presbylens is now involved in a study in Mexico with the objective of a U.S. Food and Drug Administration trial by the end of 2009. The current pre-FDA study is being done in Monterrey, Mexico, by Enrique Barragan, MD. He’s implanted the device in 18 patients, with a goal of 30 total. All patients are the target population for the implant: plano presbyopes between 45 and 65 years of age.

Read ^[1] the full article for a detailed review of the modifications that were made to the Presbylens, and how they are contributing to the lens’s current outcomes in the Mexico trial.